profit from every $100 of sales.
$0$100
60 Degrees Pharmaceuticals
$0.55-8.19% today
-88.9% in 1 year
1-year low $0.551-year high $5.20
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What 60 Degrees Pharmaceuticals sold, what it kept, and what it did with the cash.
Sales went from $223,208 in 2022 to $1.01 million in 2025, with -$7.37 million of profit last year.
SalesProfit
60 Degrees Pharmaceuticals vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| 60 Degrees Pharmaceuticals | No profit yet | ||
 Vertex Pharmaceuticals | 35.3× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 21.1× · Fair price | ||
 CSL | 22.2× · Fair price |
AI analysis
An AI analyst reads 60 Degrees Pharmaceuticals's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 1 | 1 | |
| -0 | -0 | 0 | 0 | |
| -2 | -5 | -10 | -8 | |
| -2 | -1 | -8 | -7 | |
| -6 | -4 | -8 | -7 | |
| -266.38 | -236.72 | -74.17 | -11.73 | |
| -93.7% | -87.1% | 36.7% | 22.3% | |
| -784.2% | -2,032.8% | -1,599.0% | -771.6% | |
| -2,769.5% | -1,485.1% | -1,308.0% | -732.5% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 1 | 8 | 6 | 5 |
| Cash | 0 | 2 | 2 | 2 |
| Total debt | 22 | 0 | 0 | 0 |
| Total liabilities | 25 | 3 | 2 | 2 |
| -24 | 5 | 4 | 3 | |
| 0 | 0 | 0 | 1 | |
| – | -23.9% | -149.8% | -160.8% | |
| 26.2% | -77.3% | -196.9% | -212.7% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -1 | -5 | -6 | -7 | |
| 0 | 0 | 0 | 0 | |
| -1 | -5 | -6 | -7 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 0 | 2 | 4 | 0 |
Valuation
- –
- –
- –
- 0.3×
- 1.9×
- –
- –
- -367.9%
- -383.4%
- 0.0%
Profitability
- 22.3%
- -771.6%
- -732.5%
- -723.8%
- -219.7%
- -56.2%
- -204.2%
- -137.3%
- -220.2%
- 209.5%
Growth
- +65.2%
- –
- −21.2%
- –
- −17.5%
Financial health
- -0.2×
- 0.04
- 2.8%
- -994.1×
- 2.66
- 2.30
- 0.19
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 9%of 868
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 15, 2026 | -1.28 | -0.76 | −68.4% |
| Mar 26, 2026 | -1.91 | -2.28 | +16.2% |
| Nov 13, 2025 | -2.64 | -1.84 | −43.5% |
| Aug 13, 2025 | -1.25 | -1.24 | −0.8% |
| May 15, 2025 | -1.56 | -1.31 | −19.1% |
| Mar 27, 2025 | -14.20 | -4.01 | −254.1% |
| Nov 14, 2024 | -4.65 | -3.00 | −55.0% |
| Aug 14, 2024 | -21.15 | -19.80 | −6.8% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
55No pass
Benjamin Graham
75Pass
Philip Fisher
47No pass
Peter Lynch
99Pass
Joel Greenblatt
0No pass
Charlie Munger
43No pass
Terry Smith
41No pass
Questions about 60 Degrees Pharmaceuticals
Is 60 Degrees Pharmaceuticals a good stock to buy?
A business with weak numbers that is not profitable yet. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the 60 Degrees Pharmaceuticals AI analysis
What does 60 Degrees Pharmaceuticals do?
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria preventative treatment. It is in Biotechnology.
Does 60 Degrees Pharmaceuticals pay a dividend?
No. 60 Degrees Pharmaceuticals does not pay a dividend at the moment.
Is 60 Degrees Pharmaceuticals stock halal?
No. 60 Degrees Pharmaceuticals does not pass our halal screen: its cash and confirmed interest-bearing investments are 79% of its market value, at or above the 33% limit. How we check
How has 60 Degrees Pharmaceuticals stock done over the past year?
Down 88.9% over the past twelve months, to $0.55. It traded between $0.55 and $5.20 and is 89.5% below its high.
Who are 60 Degrees Pharmaceuticals's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with 60 Degrees Pharmaceuticals's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.